EUPRAXIA PHARMACEUTICALS INC (EPRX) Fundamental Analysis & Valuation

NASDAQ:EPRX • CA29842P1053

Current stock price

6.86 USD
-0.22 (-3.11%)
Last:

This EPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EPRX Profitability Analysis

1.1 Basic Checks

  • EPRX had negative earnings in the past year.
  • EPRX had a negative operating cash flow in the past year.
  • In the past 5 years EPRX always reported negative net income.
  • In the past 5 years EPRX always reported negative operating cash flow.
EPRX Yearly Net Income VS EBIT VS OCF VS FCFEPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -44.78%, EPRX is in line with its industry, outperforming 50.68% of the companies in the same industry.
  • EPRX has a better Return On Equity (-47.02%) than 64.41% of its industry peers.
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROIC N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
EPRX Yearly ROA, ROE, ROICEPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EPRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX Yearly Profit, Operating, Gross MarginsEPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EPRX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EPRX has more shares outstanding
  • The number of shares outstanding for EPRX has been increased compared to 5 years ago.
  • EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX Yearly Shares OutstandingEPRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
EPRX Yearly Total Debt VS Total AssetsEPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 58.51 indicates that EPRX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 58.51, EPRX belongs to the best of the industry, outperforming 96.33% of the companies in the same industry.
  • There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 58.51
ROIC/WACCN/A
WACCN/A
EPRX Yearly LT Debt VS Equity VS FCFEPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 15.12 indicates that EPRX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 15.12, EPRX belongs to the best of the industry, outperforming 92.07% of the companies in the same industry.
  • EPRX has a Quick Ratio of 15.12. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
  • EPRX has a better Quick ratio (15.12) than 92.07% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
EPRX Yearly Current Assets VS Current LiabilitesEPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EPRX Growth Analysis

3.1 Past

  • The earnings per share for EPRX have decreased strongly by -18.82% in the last year.
EPS 1Y (TTM)-18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • EPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.76% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.75%
EPS Next 2Y28.54%
EPS Next 3Y13.46%
EPS Next 5Y19.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
  • Also next year EPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX Price Earnings VS Forward Price EarningsEPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX Per share dataEPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EPRX's earnings are expected to grow with 13.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.54%
EPS Next 3Y13.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPRX Dividend Analysis

5.1 Amount

  • EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EPRX Fundamentals: All Metrics, Ratios and Statistics

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (4/10/2026, 8:19:24 PM)

6.86

-0.22 (-3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners30.93%
Inst Owner Change0%
Ins Owners16.03%
Ins Owner ChangeN/A
Market Cap414.48M
Revenue(TTM)N/A
Net Income(TTM)-38.58M
Analysts85.45
Price Target11.73 (70.99%)
Short Float %4.99%
Short Ratio10.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.55%
Min EPS beat(2)-112.68%
Max EPS beat(2)-18.41%
EPS beat(4)0
Avg EPS beat(4)-49.13%
Min EPS beat(4)-112.68%
Max EPS beat(4)-18.41%
EPS beat(8)3
Avg EPS beat(8)-30.41%
EPS beat(12)6
Avg EPS beat(12)-19.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.67%
EPS NQ rev (1m)19.68%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.98
P/tB 4.98
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS1.38
TBVpS1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 247.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 58.51
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.74%
Cap/Depr(5y)191.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.23%
EPS Next Y32.75%
EPS Next 2Y28.54%
EPS Next 3Y13.46%
EPS Next 5Y19.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.5%
EBIT Next 3Y12.81%
EBIT Next 5Y29.94%
FCF growth 1Y3.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.


What is the valuation status for EPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX). This can be considered as Overvalued.


What is the profitability of EPRX stock?

EUPRAXIA PHARMACEUTICALS INC (EPRX) has a profitability rating of 1 / 10.